Skip to main content
Clinical Trials/NCT05455879
NCT05455879
Completed
Not Applicable

Impact of the Number of Doses of Antenatal Corticosteroid Therapy on the Number of Doses of Surfactants Postnatal in Preterm Infants

Hôpital NOVO1 site in 1 country145 target enrollmentJune 20, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hyaline Membrane Disease (HMD)
Sponsor
Hôpital NOVO
Enrollment
145
Locations
1
Primary Endpoint
Assessment of the effect of a full course of antenatal corticosteroid therapy versus a half course on the number of postnatal surfactant doses in preterm infants.
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

No study has shown that two doses of corticosteroids are more effective than a single dose in lung maturation and prevention of hyaline membrane disease (HMD) The aim of this study is to assess the impact of the number of doses on the severity of HMD.

Detailed Description

Respiratory distress syndrome (RDS), formerly known as hyaline membrane disease, is a common problem in preterm infants. This disorder is caused primarily by deficiency of pulmonary surfactant in an immature lung. RDS is a major cause of morbidity and mortality in preterm infants. Surfactant therapy has been shown to significantly reduce neonatal and infant mortality. Corticosteroids are given antenatal, and then surfactant is given, along with corticosteroids, postnatal. A single course of corticosteroids is recommended for pregnant women between 24 weeks and 34 weeks of gestation who are at risk of preterm delivery within 7 days, including those with ruptured membranes and multiple pregnancies. Betamethasone is recommended as the steroid of choice, to be administered in two doses of 12 mg given intramuscularly 24 hours apart.

Registry
clinicaltrials.gov
Start Date
June 20, 2022
End Date
July 5, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hôpital NOVO
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Preterm infants ≤ 37 SA
  • Hospitalized in the neonatal intensive care unit between January 2018 and December 2019
  • Having received at least one dose of corticosteroids antenatal

Exclusion Criteria

  • Parental Opposition
  • Congenital malformations that may cause neonatal respiratory distress.

Outcomes

Primary Outcomes

Assessment of the effect of a full course of antenatal corticosteroid therapy versus a half course on the number of postnatal surfactant doses in preterm infants.

Time Frame: At the end of the study, an average of 2 month

Comparison of the number of doses of surfactants administered postnatal in preterm infants who received 2 doses of antenatal corticosteroid therapy versus those who received a single dose

Secondary Outcomes

  • Assessment of the influence of the cause of prematurity on the severity of hyaline membrane disease (HMD)(At the end of the study, an average of 2 month)
  • Assessment of the influence of gestational age on the severity of hyaline membrane disease (HMD)(At the end of the study, an average of 2 month)
  • Assessment of the impact of the number of doses of antenatal corticosteroid therapy on the use of postnatal corticosteroid therapy(At the end of the study, an average of 2 month)
  • Assessment of the impact of the number of doses of antenatal corticosteroid therapy on the severity of intraventricular hemorrhage(At the end of the study, an average of 2 month)
  • Assessment of the impact of the number of doses of antenatal corticosteroid therapy on the prevalence of bronchopulmonary dysplasia(At the end of the study, an average of 2 month)

Study Sites (1)

Loading locations...

Similar Trials